Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 4/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000491 | 0.83 | PTPN2 (0.43) | PTPN2PTPN1MAPTPPARDPPARA | |
| SCHEMBL6000533 | 0.83 | PTPN2 (0.46) | PTPN2PTPN1KMT2AMEN1TDP1 | |
| SCHEMBL6000522 | 0.80 | PTPN2 (0.44) | PTPN2PTPN1KMT2AMEN1TDP1 | |
| SCHEMBL6000546 | 0.79 | PTPN2 (0.55) | PTPN2PTPN1KMT2AMEN1TDP1 | |
| SCHEMBL6001133 | 0.79 | PTPN2 (0.40) | PTPN2PTPN1KMT2AMEN1MAPT | |
| SCHEMBL6000850 | 0.75 | PTPN2 (0.54) | PTPN2PTPN1KMT2AMEN1TDP1 | |
| SCHEMBL6000524 | 0.75 | PTPN2 (0.50) | PTPN2PTPN1KMT2AMEN1TDP1 | |
| SCHEMBL6000675 | 0.74 | PTPN1 (0.37) | PTPN2PTPN1KMT2AMEN1MAPT | |
| SCHEMBL6000860 | 0.73 | PTPN2 (0.48) | PTPN2PTPN1KMT2AMEN1POLB | |
| SCHEMBL6001057 | 0.68 | PTPN2 (0.64) | PTPN2PTPN1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | PTPN11, PTPN1, PTPN3 | PTPN2 11/4885PTPN1 2/4885KMT2A 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.